Morphosys' Pelabresib: New shine after setback
Stock Rises and Hope for Myelofibrosis Patients Thanks to Promising Phase 3 Results

The German biotech company Morphosys recently published promising results from a phase 3 study involving its hopeful pelabresib. This cancer drug plays a crucial role for the company and its future prospects. The study examined the effect of a combination of pelabresib and ruxolitinib, the current standard therapy for the rare malignant bone marrow disease myelofibrosis, compared to a placebo in combination with ruxolitinib. The results, announced by Morphosys on Monday, show significant improvement in all disease characteristics.
Investors reacted extremely positively to this news, and Morphosys shares rose by an impressive twelve percent to just under 28 euros at the start of trading. This meant that the losses that the company had to accept in November due to disappointing study data were fully compensated. Nevertheless, the price is still well below the annual high of 32.45 euros reached in September.
The gloomy outlook caused the Morphosys share price to plunge by more than 30 percent on November 21, when the expected study data on pelabresib failed to convince investors. Although the main goal of the study was achieved, the drug was only able to adequately improve the symptoms of the disease, which was an important secondary goal of the study.
However, the latest results from the Phase 3 study, presented at the 65th Annual Meeting of the American Society of Hematology (ASH) in San Diego, California, have now given investors hope again. The study showed significant improvements in all four key features of myelofibrosis, which include spleen size, anemia, bone marrow fibrosis and disease-related symptoms. Raajit K. Rampal, director of the Center for Hematologic Malignancies and the Myeloproliferative Neoplasms Program at Memorial Sloan-Kettering Cancer Center, emphasized the significance of the findings. Reducing the size of the spleen is particularly important because it is linked to patient survival. In addition, the study showed that the combination of pelabresib and ruxolitinib was not only well tolerated but also effective in treating anemia, disease-related symptoms and bone marrow fibrosis.
Morphosys acquired pelabresib through the takeover of US cancer specialist Constellation Pharma for $1.7 billion and plans to apply for approval of the drug in the US and Europe next year. The promising results of this phase 3 study could initiate a paradigm shift in the treatment of myelofibrosis and set the company on a successful path in cancer drug development. Investors are once again optimistic and Morphosys' future appears brighter than ever.





